Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1986-02-20
1987-05-19
Meyers, Albert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549264, 435119, 435253, 435822, C07D49322, A61K 31365
Patent
active
046669370
ABSTRACT:
There are disclosed novel compounds which are derived from 22,23-dihydro avermectin Bla aglycone, 13-deoxy-22,23 dihydro overmectin Bla aglycone and 13-deoxy-22,23-dihydro overmectin Blb aglycone. The six compounds are hydroxy adducts of the substrate avermectin compound at the 12a, 24, 24a, 26, 26a and 27 positions. The hydroxy adducts are prepared by incubating the substrate with the microorganism Cunninghamella blakesleeana and isolating the hydroxy adducts from the fermentation broth. The compounds are highly potent antiparasitic, insecticidal and anthelmintic agents.
REFERENCES:
patent: 4199569 (1980-04-01), Chabala et al.
patent: 4206205 (1980-06-01), Mrozik et al.
patent: 4310519 (1982-01-01), Albers-Schonberg et al.
patent: 4530921 (1985-07-01), Mrozik
patent: 4582852 (1986-04-01), Gehret
Goegelman Robert T.
Inamine Edward S.
White Raymond F.
Dinner Dara
Merck & Co. , Inc.
Meyers Albert T.
Rose David L.
Sudol, Jr. Michael C.
LandOfFree
Avermectin bioconversion products does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Avermectin bioconversion products, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avermectin bioconversion products will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1565237